267 related articles for article (PubMed ID: 20614946)
1. Current and future management options for myelodysplastic syndromes.
Bryan J; Jabbour E; Prescott H; Garcia-Manero G; Issa JP; Kantarjian H
Drugs; 2010 Jul; 70(11):1381-94. PubMed ID: 20614946
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Ishikawa T
Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies for myelodysplastic syndromes.
Steensma DP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):423-41. PubMed ID: 20359635
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
5. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
7. Risk-based management of myelodysplastic syndrome.
Steensma DP; Tefferi A
Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
[TBL] [Abstract][Full Text] [Related]
8. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Robak T; Szmigielska-Kapłon A; Pluta A; Grzybowska-Izydorczyk O; Wolska A; Czemerska M; Wierzbowska A
Curr Med Chem; 2011; 18(5):638-66. PubMed ID: 21182488
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine in the treatment of myelodysplastic syndromes.
Bryan J; Kantarjian H; Prescott H; Jabbour E
Expert Opin Investig Drugs; 2014 Feb; 23(2):255-63. PubMed ID: 24410313
[TBL] [Abstract][Full Text] [Related]
10. Clofarabine for myelodysplastic syndromes.
Tiu RV; Traina F; Sekeres MA
Expert Opin Investig Drugs; 2011 Jul; 20(7):1005-14. PubMed ID: 21591997
[TBL] [Abstract][Full Text] [Related]
11. Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib J; Greenberg PL
J Natl Compr Canc Netw; 2003 Oct; 1(4):473-80. PubMed ID: 19774739
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Ball B; Zeidan A; Gore SD; Prebet T
Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
14. [Supportive therapy for myelodysplastic syndrome (MDS). Indispensable pillar in the multimodal treatment concept].
Göbel A; Lubrich B
Pharm Unserer Zeit; 2010 May; 39(3):228-33. PubMed ID: 20425777
[No Abstract] [Full Text] [Related]
15. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg PL; Cosler LE; Ferro SA; Lyman GH
J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
[TBL] [Abstract][Full Text] [Related]
16. [Novel medical treatment modalities in hematology].
Hasselbalch HC; Birgens H; Dufva IH; Dalseg AM; Brown Pde N; Jensen MK; Vangsted A
Ugeskr Laeger; 2008 Jun; 170(24):2115-9. PubMed ID: 18565291
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic growth factors in myelodysplastic syndromes.
Steensma DP
Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
[TBL] [Abstract][Full Text] [Related]
18. Management of myelodysplastic syndromes in the geriatric patient.
Ritchie EK; Lachs MS
Curr Hematol Malig Rep; 2009 Jan; 4(1):3-9. PubMed ID: 20425432
[TBL] [Abstract][Full Text] [Related]
19. Treatment of MDS: something old, something new, something borrowed..
Sekeres MA
Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251
[TBL] [Abstract][Full Text] [Related]
20. Management of myelodysplastic syndromes: 2008 update.
Scott BL; Estey E
Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
